Why carry out this study?

Rheumatoid arthritis (RA) is a chronic disease requiring long-term treatment; therefore an understanding of the long-term effectiveness, safety, and tolerability of an RA therapy is key.

Interim results from an open-label long-term extension (LTE) study of peficitinib (ASP015K), a pan-Janus kinase inhibitor, in Asian patients with RA, have been published.

This final analysis of the LTE study assessed the long-term safety, tolerability, and effectiveness of peficitinib in Asian patients with RA, over a mean 32 months of treatment.

What was learned from this study?

This study showed that improvements in American College of Rheumatology response and other effectiveness variables were maintained during long-term peficitinib treatment, and peficitinib was generally well tolerated in Asian patients with RA.

These final data support peficitinib use for the long-term management of RA in Asian patients.